Cary Street Partners Investment Advisory’s Eledon Pharmaceuticals ELDN Stock Holding History

Cary Street Partners Investment Advisory’s Portfolio ELDN Stock Details ELDN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	$22K	Buy	+589	New	+$37.6K	0.02%	103

Other funds holding ELDN

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BRWA

B. Riley Wealth Advisors Boca Raton, Florida $1.87B AUM 37.01% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SFA

Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

RJA

Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return

Cary Street Partners Investment Advisory's ELDN Position: Q4 2018 in Review

Cary Street Partners Investment Advisory opened a new position in Eledon Pharmaceuticals (ELDN) in Q4 2018: 589 shares worth $22K. The stake represents 0.02% of the portfolio and ranks #103 among its holdings.

16 funds tracked by Wall St. Rank hold ELDN as of Q4 2018.

Cary Street Partners Investment Advisory held 589 shares of Eledon Pharmaceuticals worth $22K as of Q4 2018.
Eledon Pharmaceuticals was a new Cary Street Partners Investment Advisory position in Q4 2018.
Eledon Pharmaceuticals made up 0.02% of Cary Street Partners Investment Advisory's portfolio in Q4 2018, its #103 holding.
16 funds tracked by Wall St. Rank held Eledon Pharmaceuticals as of Q4 2018.

Based on Cary Street Partners Investment Advisory's 13F filing for Q4 2018, filed 6 Feb 2019.